Regeneron Pharmaceuticals, Inc. 8-K Filing

Ticker: REGN · Form: 8-K · Filed: Jan 13, 2025 · CIK: 872589

Regeneron Pharmaceuticals, Inc. 8-K Filing Summary
FieldDetail
CompanyRegeneron Pharmaceuticals, Inc. (REGN)
Form Type8-K
Filed DateJan 13, 2025
Pages5
Reading Time5 min
Key Dollar Amounts$0.001, $14 million, $0.11
Sentimentneutral

Sentiment: neutral

FAQ

What type of filing is this?

This is a 8-K filing submitted by Regeneron Pharmaceuticals, Inc. (ticker: REGN) to the SEC on Jan 13, 2025.

What are the key financial figures in this filing?

Key dollar amounts include: $0.001 (h registered Common Stock – par value $0.001 per share REGN NASDAQ Global Select M); $14 million (ent (" IPR&D ") charge of approximately $14 million on a pre-tax basis. This charge primari); $0.11 (he fourth quarter 2024 by approximately $0.11. Acquired IPR&D charges may include IP).

How long is this filing?

Regeneron Pharmaceuticals, Inc.'s 8-K filing is 5 pages with approximately 1,366 words. Estimated reading time is 5 minutes.

Where can I view the full 8-K filing?

The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.

Filing Stats: 1,366 words · 5 min read · ~5 pages · Grade level 11.2 · Accepted 2025-01-13 06:37:41

Key Financial Figures

  • $0.001 — h registered Common Stock – par value $0.001 per share REGN NASDAQ Global Select M
  • $14 million — ent (" IPR&D ") charge of approximately $14 million on a pre-tax basis. This charge primari
  • $0.11 — he fourth quarter 2024 by approximately $0.11. Acquired IPR&D charges may include IP

Filing Documents

02

Item 2.02. Results of Operations and Financial Condition. On January 13, 2025, Regeneron Pharmaceuticals, Inc. (" Regeneron " or the " Company ") issued a press release titled "Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference." The press release and the Company's January 13, 2025 conference presentation contain certain preliminary (unaudited) financial information for the fourth quarter and full year 2024 and are being furnished to the Securities and Exchange Commission as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K, respectively, and incorporated by reference in this Item 2.02. Additionally, the Company currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles (" GAAP ") and its non-GAAP financial results for the fourth quarter 2024 will include an acquired in-process research and development (" IPR&D ") charge of approximately $14 million on a pre-tax basis. This charge primarily relates to asset acquisitions. This acquired IPR&D charge is expected to negatively impact each of GAAP and non-GAAP net income per diluted share for the fourth quarter 2024 by approximately $0.11. Acquired IPR&D charges may include IPR&D acquired in connection with asset acquisitions as well as premiums paid on equity securities and up-front, opt-in, and certain development milestone payments related to collaboration and licensing agreements. Regeneron does not forecast such acquired IPR&D charges due to the uncertainty of the future occurrence, magnitude, and timing of these transactions in any given period. Regeneron's results for the fourth quarter and full year 2024 have not been finalized and are subject to Regeneron's financial statement closing procedures. There can be no assurance that actual results will not differ from the preliminary (unaudited) estimates described or incorporated by reference herein.

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. The information set forth under Item 2.02 of this Current Report on Form 8-K is incorporated by reference herein. Copies of the press release and the presentation referenced in Item 2.02 are furnished as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K and are incorporated by reference in this Item 7.01. The information included or incorporated in Item 2.02 and the information included or incorporated in Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information and exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. 99.1 Press Release, dated January 13, 2025, titled "Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference." 99.2 Presentation, dated January 13, 2025, by Leonard S. Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive Officer of Regeneron Pharmaceuticals, Inc., and George D. Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer of Regeneron Pharmaceuticals, Inc., at the 43rd Annual J.P. Morgan Healthcare Conference. 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document. Note Regarding Forward-Looking Statements This Current Report on Form 8-K (this "Report") includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company"), and actual events or results may differ materially from these forward-looking statements. Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, Regeneron's expectations with respect to commercialization of its marketed products, competitive and other relevant developments affecting the market share of Regeneron's marketed products, and other relevant factors (whether within or without Regeneron's control) impacting the degree to which commercialization of Regeneron's marketed products is successful, as well as the impact of any of the foregoing on Regeneron's results of operations; and Regeneron's expected acquired in-process research and development charge for the quarterly pe

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REGENERON PHARMACEUTICALS, INC. /s/ Joseph J. LaRosa Joseph J. LaRosa Executive Vice President, General Counsel and Secretary Date: January 13, 2025

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.